secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-051565
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q1 net loss $55.4M ($0.09/shr); PDUFA for imetelstat June 16, 2024
------------------------------------------------------------------------

- Q1 net loss of $55.4M ($0.09/shr) vs $38.1M ($0.07/shr) in Q1 2023; revenue $304K.
- Cash and marketable securities $465M as of March 31, 2024; $80M principal debt outstanding.
- FDA ODAC voted 12-2 in favor of imetelstat benefit/risk for lower-risk MDS; PDUFA date June 16, 2024.
- IMpactMF trial timelines extended 6 months: interim analysis now early 2026, final early 2027.
- FY2024 total operating expense guidance $270M-$280M; commercial team onboarded in April.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/0000950170-24-051565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/gern-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer